Abstract
Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Current Gene Therapy
Title: Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Volume: 2 Issue: 1
Author(s): Antoni Ribas, Lisa H. Butterfield, John A. Glaspy and James S. Economou
Affiliation:
Keywords: Cancer Immunotherapy, Gene-Modified Dendritic Cells, immunostimulatory molecules, proteasome complex, Viral Vector Transduction, Takayama
Abstract: Gene-engineered dendritic cells (DC) are being tested in cancer immunotherapy. DC are the best equipped antigen-presenting cells (APC) to overcome tolerance / ignorance to self antigens presented by cancer cells. Genetic immunotherapy with DC engineered to express tumor antigens has the potential advantages of endogenous epitope presentation by both major histocompatibility complex (MHC) class I and II molecules. DC can also be gene-modified to express immunostimulatory molecules that further enhance their antigen-presenting function. Review of the literature provided 52 manuscripts where gene-modified DC were being tested in murine models of immunotherapy for cancer. Review of the antitumor effects of gene-modified DC in these preclinical studies provides valuable information on the optimal methods of gene transfer into DC, the schedule of administration, the route, dose and the underlying immunological mechanisms of the antitumor effects. These data may help in the translation of this promising approach to the clinic.
Export Options
About this article
Cite this article as:
Ribas Antoni, Butterfield H. Lisa, Glaspy A. John and Economou S. James, Cancer Immunotherapy Using Gene-Modified Dendritic Cells, Current Gene Therapy 2002; 2 (1) . https://dx.doi.org/10.2174/1566523023348129
DOI https://dx.doi.org/10.2174/1566523023348129 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Novel Natural Polymers Based Nanoparticles Gel Formulation for the Treatment of Rheumatoid Arthritis: Optimization and <i>In-vivo</i> Evaluation
Drug Delivery Letters Preclinical Studies of Alkylureas as Anti-HIV-1 Contraceptive
Current Pharmaceutical Design The Effect of Educational Intervention Based on Health Belief Model on Beliefs Towards Human Papillomavirus Vaccination in a Sample of Iranian Female Nursing Students
Current Women`s Health Reviews Current Status of Anti-HIV Agents
Current Medicinal Chemistry - Anti-Infective Agents Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews Strategies to Improve Insulin Delivery through Oral Route: A Review
Current Drug Delivery Recent Advances in Thermosensitive Hydrogels as Drug Delivery Systems: A Review
Drug Delivery Letters Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Critical Illness in Obstetric Patients: Venous Thromboembolism in Pregnancy
Current Women`s Health Reviews Transcriptional Regulation of Antimicrobial Host Defense Peptides
Current Protein & Peptide Science Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry Colorectal Cancer – Increased Multidimensional Understanding of the Molecular Genesis
Current Cancer Therapy Reviews Candidiasis: A Fungal Infection- Current Challenges and Progress in Prevention and Treatment
Infectious Disorders - Drug Targets Ex Vivo Models of HIV Sexual Transmission and Microbicide Development
Current HIV Research Survey of Functional Activities of Alpha-fetoprotein Derived Growth Inhibitory Peptides: Review and Prospects
Current Protein & Peptide Science Mucoadhesive Polymeric Platform for Drug Delivery; A Comprehensive Review
Current Drug Delivery Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews